ライフサイエンスコーパス: EHV-1

1 EHV-1 and BHV-1 Us9 were able to fully compensate for th

2 EHV-1 entry was thought to occur exclusively through fus

3 EHV-1 productively infected four of these cell lines, an

4 EHV-1 strain KyA is attenuated in the mouse and equine,

5 EHV-1-specific CTL could be restimulated from the spleen

6 The equine herpesvirus 1 (EHV-1) alpha-trans-inducing factor homologue (ETIF; VP16

7 h the alphaherpesvirus equine herpesvirus 1 (EHV-1) displayed reduced body weight loss but had higher

8 t the alphaherpesvirus equine herpesvirus 1 (EHV-1) efficiently entered and replicated in CHO-K1 cell

9 placed with the SRT of equine herpesvirus 1 (EHV-1) IEP, its trans-activation activity was completely

10 The equine herpesvirus 1 (EHV-1) immediate-early (IE) and EICP0 proteins are poten

11 The equine herpesvirus 1 (EHV-1) immediate-early (IE) phosphoprotein is essential

12 iratory infection with equine herpesvirus 1 (EHV-1) in CBA (H-2(k)) mice was investigated.

13 best option to combat equine herpesvirus 1 (EHV-1) infection, and several different strategies of va

14 Equine herpesvirus 1 (EHV-1) is a major pathogen affecting equines worldwide.

15 Equine herpesvirus 1 (EHV-1) is a member of the Alphaherpesvirinae, and its br

16 2 protein (EICP22P) of Equine herpesvirus 1 (EHV-1) is an early protein that functions synergisticall

17 The EICP0 protein of equine herpesvirus 1 (EHV-1) is an early, viral regulatory protein that indepe

18 tivates all classes of equine herpesvirus 1 (EHV-1) promoters but, unexpectedly, trans-activates its

19 iently transduced with equine herpesvirus 1 (EHV-1) reconstituted from viral DNA maintained and manip

20 lung by the pathogenic equine herpesvirus 1 (EHV-1) strain RacL11 in comparison to infection with the

21 Wild-type equine herpesvirus 1 (EHV-1) strains express a large (250-kDa) glycoprotein, g

22 Most equine herpesvirus 1 (EHV-1) strains, including the naturally occurring virule

23 rus type 1 (HSV-1) and equine herpesvirus 1 (EHV-1), and of channel catfish virus, an evolutionarily

24 er alphaherpesviruses: equine herpesvirus 1 (EHV-1), varicella-zoster virus, and pseudorabies virus,

25 t 5 h postinfection in equine herpesvirus 1 (EHV-1)-infected HeLa and equine NBL6 cells.

26 athogenic phenotype of equine herpesvirus-1 (EHV-1).

27 rinary pathogens, equine herpesvirus type 1 (EHV-1) and bovine herpesvirus type 1 (BHV-1), and fused

28 (DI) particles of equine herpesvirus type 1 (EHV-1) are capable of mediating persistent infection.

29 Here, we used equine herpesvirus type 1 (EHV-1) as a model to determine residues in EHV-1 gG that

30 is study, we used equine herpesvirus type 1 (EHV-1) as a model to study the pathophysiological import

31 ype 1 (HSV-1) and equine herpesvirus type 1 (EHV-1) failed to support DNA replication in cells.

32 s the role of the equine herpesvirus type 1 (EHV-1) ICP0 protein (EICP0) in gene regulation, a variet

33 ytic animal virus equine herpesvirus type 1 (EHV-1) was evaluated for its oncolytic potential against

34 Equine herpesvirus type 1 (EHV-1), a member of the Alphaherpesviridae, displays a b

35 s type 1 (BHV-1), equine herpesvirus type 1 (EHV-1), pseudorabies virus (PRV), and varicella-zoster v

36 alphaherpesvirus equine herpesvirus type 1 (EHV-1).

37 The BHV-1, EHV-1, and PRV proteins complement ICP0-null mutant HSV-

38 howed that the EICP0 protein trans-activated EHV-1 promoters harboring only a minimal promoter region

39 y protein that independently trans-activates EHV-1 immediate-early (IE), early, gamma1 late, and gamm

40 sting that the EICP0 protein trans-activates EHV-1 promoters by interactions with general transcripti

41 In addition, EHV-1 infection of the B78H1 MHC-I-expressing cell lines

42 gesting that it could protect horses against EHV-1 infection.

43 HC-I, indicating that human MHC-I acts as an EHV-1 entry receptor on glioma cells.

44 binant virus was constructed by inserting an EHV-1 gD expression cassette under the control of the cy

45 oma cells, these cells were infected with an EHV-1 lacZ reporter virus, and cells that supported viru

46 r new strategies for the development of anti-EHV-1 agents in the equine.

47 together to significantly trans-activate any EHV-1 promoter, and (iv) the EICP27 and EICP0 proteins f

48 e, this is the first report of an attenuated EHV-1 vaccine that protects the animal at 1 to 7 days po

49 t EHV-1 KyA may be used as a live attenuated EHV-1 vaccine as well as a prophylactic agent in horses.

50 .n.) inoculation of mice with the attenuated EHV-1 strain KyA resulted in the generation of a primary

51 The attenuated EHV-1 vaccine strain KyA harbors an in-frame deletion of

52 Because EHV-1 was not neutralized by human sera containing high

53 The administration of IFN-gamma blocked EHV-1 replication in murine alveolar macrophages and mou

54 ive regulator of ROCK1 significantly blocked EHV-1 infection.

55 protein; and (iv) the EICP0 protein of both EHV-1 strains is a potent transactivator of EHV-1 genes.

56 Therefore, a new allelic discrimination EHV-1 rPCR assay (E(1)) was developed by redesigning pri

57 ed that (i) the IR2P by itself downregulated EHV-1 early promoters (EICP0, TK, EICP22, and EICP27) in

58 As with other alphaherpesviruses, efficient EHV-1 entry was dependent on glycoprotein D and cell sur

59 Infection with either EHV-1 strain resulted in the accumulation of similar num

60 An ETIF-null mutant from EHV-1 strain RacL11 (vL11deltaETIF) was constructed and

61 ough this rPCR assay can detect and genotype EHV-1 strains, subsequent studies demonstrated that it l

62 these T-cell populations revealed identical EHV-1-specific cytotoxic T-lymphocyte responses.

63 The TADs of IE62, EHV-1 IEP, and HSV-1 VP16 interacted with cellular Media

64 entation assays showed that the TAD of IE62, EHV-1 IEP, and HSV-1 VP16 interacted with Mediator 25 in

65 ected cells; however, the amount of NREBP in EHV-1-infected L-M cells that bound to the Nb oligonucle

66 rapid early host protein shutoff occurred in EHV-1-infected cells led us to test EHV-1 vhs activity m

67 an important role for the EICP22 protein in EHV-1 gene regulation.

68 (EHV-1) as a model to determine residues in EHV-1 gG that are involved in the processes of chemokine

69 Murine IFN-gamma inhibited EHV-1 infection of murine alveolar macrophages and prote

70 V-1-susceptible cell type were inserted into EHV-1-resistant B78H1 murine melanoma cells, these cells

71 corresponding mutations were introduced into EHV-1 UL8.

72 acrophages and protected mice against lethal EHV-1 challenge, suggesting that IFN-gamma expression is

73 ially neuropathogenic and nonneuropathogenic EHV-1 strains.

74 This novel EHV-1 receptor was discovered using a cDNA library from

75 r was absolutely essential for activation of EHV-1 promoters, since deletion of the entire RING finge

76 ICP0 proteins are potent trans-activators of EHV-1 promoters; however, in transient-transfection assa

77 Analysis of EHV-1-reactive IgG subtypes demonstrated that vaccinatio

78 nt for the trans-activation of each class of EHV-1 promoters.

79 f representative promoters of all classes of EHV-1 genes and contains a negative regulatory element (

80 sufficient for activation of all classes of EHV-1 promoters, (iii) the RING finger was absolutely es

81 sential function in the replication cycle of EHV-1, and its main role appears to be in secondary enve

82 ion of full-length gp2 in the development of EHV-1 vaccines.

83 In the present study, the effects of EHV-1 and HSV-1 infections on cellular protein synthesis

84 may function in the coordinate expression of EHV-1 genes.

85 a vector for the heterologous expression of EHV-1 glycoprotein D (gD) and that the intramuscular imm

86 Here we report on the function of EHV-1 ETIF in the context of viral infection.

87 or the detection and A/G(2254) genotyping of EHV-1, making this improved rPCR assay a valuable diagno

88 , comprehensive analysis of glycosylation of EHV-1 gG revealed that N-glycosylation is not required f

89 After intranasal instillation of EHV-1 into mice, efficient transgene expression in lungs

90 antly, in vivo analyses in a murine model of EHV-1 infection showed that neutrophil migration in the

91 The NREBP is also present in the nucleus of EHV-1-infected cells; however, the amount of NREBP in EH

92 agnostic tool for investigating outbreaks of EHV-1 infection.

93 of ORF30 was used to confirm the presence of EHV-1 and characterize the genotype (A(2254) or G(2254))

94 d glycoproteins the hypervariable regions of EHV-1 gG, a vCKBP, and the closely related EHV-4 gG, whi

95 ta5, are important during the early steps of EHV-1 entry via endocytosis in CHO-K1 cells.

96 In such assays, supernatants of EHV-1-infected cells significantly inhibited IL-8-induce

97 e not essential for EICP0 transactivation of EHV-1 promoters.

98 EHV-1 strains is a potent transactivator of EHV-1 genes.

99 ld be transduced with one infectious unit of EHV-1 per cell.

100 When inserted into the promoters of other EHV-1 genes, this sequence also downregulated activation

101 or functions in conjunction with three other EHV-1 regulatory proteins to activate expression of the

102 in that functions synergistically with other EHV-1 regulatory proteins to transactivate the expressio

103 nalysis revealed that EUs4 of the pathogenic EHV-1 strain RacL11 is an open reading frame of 2,376 bp

104 lammatory response induced by the pathogenic EHV-1 strain RacL11.

105 munity against infection with the pathogenic EHV-1 strain, RacL11.

106 on and virus growth assays, the IR2P reduced EHV-1 production by 23-fold compared to virus titers ach

107 n cooperates with the IE protein to regulate EHV-1 gene expression.

108 3 clinical specimens from cases of suspected EHV-1 infection.

109 urred in EHV-1-infected cells led us to test EHV-1 vhs activity more thoroughly and to examine the ex

110 From these results we conclude that EHV-1's low vhs activity in infected cells is not a refl

111 ors HveA, HveB, and HveC, demonstrating that EHV-1 utilizes a unique entry receptor.

112 the data in this study provide evidence that EHV-1 entry via endocytosis is triggered by the interact

113 RSD motif present in gD and, moreover, that EHV-1 uses different cellular entry pathways to infect i

114 These results show that EHV-1 can enter disparate cell types by at least two dis

115 In addition, we show that EHV-1 enters peripheral blood mononuclear cells predomin

116 We also show that EHV-1 infection requires the activation of cell signalin

117 In this study, we show that EHV-1 KyA immunization effectively protected CBA mice fr

118 aveola-dependent endocytosis, we showed that EHV-1 entry into CHO-K1 cells does not require clathrin

119 Previously, we showed that EHV-1 infects Chinese hamster ovary (CHO-K1) cells even

120 These results suggest that EHV-1 KyA may be used as a live attenuated EHV-1 vaccine

121 , and its broad tissue tropism suggests that EHV-1 may use multiple receptors to initiate virus entry

122 mary, we demonstrate for the first time that EHV-1 gG not only binds to chemokines but is also capabl

123 The EHV-1 EICP22 protein, a homolog of ICP22 of herpes simpl

124 gG variants containing the EHV-1 hypervariable region were able to bind chemokines

125 ever, further analyses revealed that (i) the EHV-1 vhs homolog gene, ORF19, was transcribed and trans

126 l analysis revealed that an RSD motif in the EHV-1 envelope glycoprotein D (gD) is critical for entry

127 equence-specific DNA-binding activity of the EHV-1 immediate-early protein (IEP).

128 o examine the expression and function of the EHV-1 UL41 homolog, ORF19.

129 The sequence data revealed that the EHV-1-susceptible cells had acquired an E. caballus MHC-

130 cDNAs from this EHV-1-susceptible cell type were inserted into EHV-1-res

131 detected in cells infected with any of three EHV-1 strains (Ab4, KyA, and KyD) at multiplicities of i

132 etermine the relative contribution of gp2 to EHV-1 pathogenesis, we compared the course of respirator

133 These cell lines were susceptible to EHV-1 infection while the parental B78H1 cells remained

134 s we conclude that full-length and truncated EHV-1 gp2 are not functionally equivalent and cannot com

135 Successful immunization using EHV-1 was shown after delivery of the human immunodefici

136 The VC2-EHV-1-gD recombinant virus was constructed by inserting

137 Vaccination with both the VC2-EHV-1-gD vaccine and the commercially available vaccine

138 s demonstrated that vaccination with the VC2-EHV-1-gD vaccine stimulated robust IgG1 and IgG2a antibo

139 nimals.IMPORTANCE A novel virus-vectored VC2-EHV-1-gD vaccine was constructed using the live-attenuat

140 Vaccination with VC2-EHV-1-gD stimulated strong cellular immune responses, ch

141 hat were shown to be uniformly infected with EHV-1.